Barrx™ radiofrequency ablation system is designed to precisely eradicate the Barrett’s epithelium.1 Barrett's esophagus patients with low-grade dyplasia treated with RFA have a substantial reduction in progression compared to patients who undergo surveillance alone.2
The Barrx™ radiofrequency ablation system includes the Barrx™ flex RFA energy generator and a family of ablation catheters.
Eradicate Barrett’s esophagus for patients with low-grade dysplasia and reduce the relative risk of disease progression to high-grade dysplasia and esophageal adenocarcinoma by up to 94% with the Barrx™ radiofrequency ablation system.2,3,7,†
Major GI societies endorse radiofrequency ablation in the treatment guidelines for Barrett’s esophagus. With demonstrated efficacy, safety,1 and support from leading institutions8,9 this technology allows you to act with confidence.
When risk of progression is high, proactively treat with the Barrx™ radiofrequency ablation system.
Progression of Barrett’s esophagus to esophageal adenocarcinoma (EAC) can be deadly.10 Surveillance may not be enough for some patients.
Clinical data has identified several risk factors that contribute to disease progression, including:
Barrx™ flex RFA energy generator
The Barrx™ radiofrequency ablation system includes the Barrx™ flex RFA energy generator and a family of ablation catheters which are designed to control depth and uniformity of gastrointestinal (GI) tissue ablation.
Barrx™ 360 express RFA balloon catheter
The Barrx™ 360 express RFA balloon catheter features a self-adjusting ablation balloon that eliminates the sizing process.
Barrx™ RFA focal catheters
The Barrx™ RFA focal catheter enables physicians to provide primary treatment for short and intermediate length segments of non-circumferential Barrett's esophagus or provide secondary treatment after ablation with the Barrx™ 360 RFA balloon catheter (or other therapeutic devices).
Barrx™ channel RFA endoscopic catheter
The Barrx™ channel RFA endoscopic catheter delivers radiofrequency ablation, after being placed through the working channel of a flexible endoscope.
Barrx™ RFA accessories
Barrx™ accessories include endoscopic guidewires, cleaning caps, and a cart to hold ablation equipment.
Our comprehensive solutions can assist you in the assessment and treatment of esophageal patients.
†94% is the calculated relative risk reduction [(26-1.5)/26] = 25/26 *100. From [25.0% (1.5% for ablation vs 26.5% for control; 95%CI, 14.1%-35.9%; P < .001].
1. Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic radiofrequency ablation for Barrett's esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy. 2010;42:781-9.
2. Phoa KN, van Vilsteren FG, Pouw RE, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014;26;311(12):1209-17.
3. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009; 28;360(22):2277-88.
4. Tofani C, Gandhi K, Spataro J, et al. Esophageal adenocarcinoma in a first-degree relative increases risk for progression to esophageal adenocarcinoma in patients with Barrett’s esophagus. Am J Gastroenterol. 2017; 309:112(1).
5. Anaparthy R, Gaddam S, Kanakadandi V, et al. Association between length of Barrett’s esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia. Clin Gastroenterol Hepatol. 2013;11(11):1430-6.
6. Helen G. Coleman, Shivaram Bhat, Brian T. Johnston, Damian Mcmanus, Anna T. Gavin, and Liam J. Murray. Tobacco smoking increases the risk of high-grade dysplasia and cancer among patients with Barrett’s esophagus. Gastroenterology. 2012;142(2):233-40.
7. Wolf WA, Pasricha S, Cotton C, et al. Incidence of esophageal adenocarcinoma and causes of mortality after radiofrequency ablation of Barrett’s esophagus. Gastroenterology. 2015;149(7):1752-1761.
8. Sharma, P., Shaheen, N., Katzka, D., Bergman, J.G.H.M. AGA Clinical Practice Update on Endoscopic Treatment of Barrett's Esophagus with Dysplasia and /or Early Cancer: Expert Review. Gastroenterology. 2020. Vol 158(3): P760-769.
9. Shaheen NJ, Falk GW, Iyer PG, Gerson, LB. ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. The American Journal of Gastroenterology. 2016;111(1):30–50.
10. https://www.cancer.org/cancer/esophagus-cancer/about/key-statistics.html Accessed date: 11/14/2022Visit Site